In the phase 2 cohort expansion (VERITAC) of this first-in-human study, the selected phase 3 monotherapy dose of vepdegestrant 200 mg once daily (QD) showed durable clinical activity in heavily pretreated patients with ER+/HER2- advanced breast cancer and had a favorable safety profile [24]. This evidence concerns the gene ESR1 and breast carcinoma.